DOCSLIB.ORG

Opinion on Methyl Salicylate (Methyl 2-Hydroxybenzoate)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SCCS/1633/21 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Scientific Committee on Consumer Safety 15 16 SCCS 17 18 19 20 21 OPINION 22 on Methyl salicylate 23 24 (methyl 2-hydroxybenzoate) 25 26 27 28 29 30 31 32 33 34 35 36 The SCCS adopted this document 37 at its plenary meeting on 24-25 June 2021 38 SCCS/1633/21 Preliminary version Opinion on methyl salicylate (methyl 2-hydroxybenzoate) 1 2 ACKNOWLEDGMENTS 3 4 Members of the Working Group are acknowledged for their valuable contribution to this Opinion. 5 The members of the Working Group are: 6 7 8 For the preliminary version 9 10 SCCS members 11 Dr U. Bernauer 12 Dr L. Bodin 13 Prof. Q. Chaudhry (SCCS Chair) 14 Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) 15 Prof. M. Dusinska 16 Dr J. Ezendam 17 Dr E. Gaffet 18 Prof. C. L. Galli 19 Dr B. Granum 20 Prof. E. Panteri 21 Prof. V. Rogiers (SCCS Vice-Chair) 22 Dr Ch. Rousselle (Rapporteur) 23 Dr M. Stepnik 24 Prof. T. Vanhaecke 25 Dr S. Wijnhoven 26 27 SCCS external experts 28 Dr A. Koutsodimou 29 Prof. W. Uter 30 Dr N. von Goetz 31 32 33 34 35 36 37 38 39 40 41 42 All Declarations of Working Group members are available on the following webpage: 43 Register of Commission expert groups and other similar entities (europa.eu) 44 45 46 47 SCCS/1633/21 Preliminary version Opinion on methyl salicylate (methyl 2-hydroxybenzoate) 1 2 1. ABSTRACT 3 4 The SCCS concludes the following: 5 6 7 (1) In light of the data provided and taking under consideration the RAC Opinion on Methyl 8 salicylate and the expected new classification as Toxic for Reproduction Category 2 of Methyl 9 salicylate (to be introduced by an update of Annex VI Reg. 1272/2008), does the SCCS 10 consider Methyl salicylate safe when used up to the maximum concentrations provided in the 11 dossier submitted by the applicant? 12 The SCCS considers Methyl salicylate safe when used in cosmetic products up to the 13 maximum concentrations provided in the dossier submitted by the applicant as detailed in 14 Table 1, except for mouth washes used below 10 years old. 15 (2) Does the SCCS have any further scientific concerns with regard to the use of Methyl salicylate 16 in cosmetic products, also in relation to the RAC recommended classification of Methyl 17 salicylate as ‘Skin sensitizer Category 1B’? 18 19 Methyl salicylate should be considered as a weak skin sensitiser in humans and eye irritant. 20 Moreover the SCCS would like also to express other concerns related to the use of methyl 21 salicylate: 22 Methyl salicylate can be used in consumer products other than cosmetic products, 23 such as household cleaning products, air care products, biocides (e.g. disinfectants, 24 pest control products), polishes and waxes which may increase the systemic 25 exposure dose with a possibility to exceed the safe level. 26 Methyl salicylate will be metabolised in the body to salicylic acid which is also 27 classified as a reprotoxicant and used in cosmetic products (see opinion 28 SCCS/1601/18). Therefore the combined exposure to cosmetic products containing 29 various salicylates may increase the systemic exposure dose with a possibility to 30 exceed the safe level. 31 The SCCS also notices that wintergreen oil that is used in cosmetic products may contain up 32 to 99% methyl salicylate. Therefore when calculating the content of methyl salicylate in a 33 cosmetic product, any fraction coming from wintergreen oil should also be considered. 34 35 36 Keywords: SCCS, scientific opinion, methyl salicylate, methyl 2-hydroxybenzoate, Regulation 37 1223/2009 38 39 Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on methyl 40 salicylate (methyl 2-hydroxybenzoate), preliminary version of 24-25 June, SCCS/1633/21 41 42 SCCS/1633/21 Preliminary version Opinion on methyl salicylate (methyl 2-hydroxybenzoate) 1 2 About the Scientific Committees 3 Two independent non-food Scientific Committees provide the Commission with the scientific 4 advice it needs when preparing policy and proposals relating to consumer safety, public health 5 and the environment. The Committees also draw the Commission's attention to the new or 6 emerging problems which may pose an actual or potential threat. 7 These Committees are: the Scientific Committee on Consumer Safety (SCCS) and the Scientific 8 Committee on Health, Environmental and Emerging Risks (SCHEER) and they are made up of 9 scientists appointed in their personal capacity. 10 In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), 11 the European Medicines Agency (EMA), the European Centre for Disease prevention and Control 12 (ECDC) and the European Chemicals Agency (ECHA). 13 SCCS 14 The Committee shall provide Opinions on questions concerning health and safety risks (notably 15 chemical, biological, mechanical and other physical risks) of non-food consumer products (for 16 example cosmetic products and their ingredients, toys, textiles, clothing, personal care and 17 household products such as detergents, etc.) and services (for example: tattooing, artificial sun 18 tanning, etc.). 19 20 Scientific Committee members 21 Ulrike Bernauer, Laurent Bodin, Qasim Chaudhry, Pieter Jan Coenraads, Maria Dusinska, Janine 22 Ezendam, Eric Gaffet, Corrado Lodovico Galli, Berit Granum, Eirini Panteri, Vera Rogiers, 23 Christophe Rousselle, Maciej Stepnik, Tamara Vanhaecke, Susan Wijnhoven 24 25 26 Contact 27 European Commission 28 Health and Food Safety 29 Directorate C: Public Health 30 Unit C2 – Health information and integration in all policies 31 L-2920 Luxembourg 32 [email protected] 33 34 © European Union, 2021 35 36 ISSN ISBN 37 Doi: ND- 38 39 The Opinions of the Scientific Committees present the views of the independent scientists who 40 are members of the committees. They do not necessarily reflect the views of the European 41 Commission. The Opinions are published by the European Commission in their original language 42 only. 43 44 http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm 45 46 47 48 SCCS/1633/21 Preliminary version Opinion on methyl salicylate (methyl 2-hydroxybenzoate) 1 2 TABLE OF CONTENTS 3 4 ACKNOWLEDGMENTS ............................................................................................. 2 5 1. ABSTRACT .................................................................................................... 3 6 2. MANDATE FROM THE EUROPEAN COMMISSION ................................................. 6 7 3. OPINION ...................................................................................................... 8 8 3.1 CHEMICAL AND PHYSICAL SPECIFICATIONS ............................................. 8 9 3.1.1 Chemical identity ................................................................................. 8 10 3.1.2 Physical form ...................................................................................... 9 11 3.1.3 Molecular weight ................................................................................. 9 12 3.1.4 Purity, composition and substance codes ................................................ 9 13 3.1.5 Impurities / accompanying contaminants.............................................. 10 14 3.1.6 Solubility .......................................................................................... 10 15 3.1.7 Partition coefficient (Log Pow) .............................................................. 10 16 3.1.8 Additional physical and chemical specifications ...................................... 10 17 3.1.9 Homogeneity and Stability .................................................................. 10 18 3.2 EXPOSURE ASSESSMENT & TOXICOKINETICS ........................................ 11 19 3.2.1 Function and uses .............................................................................. 11 20 3.2.2 Dermal / percutaneous absorption ....................................................... 12 21 3.2.3 Other studies on toxicokinetics ............................................................ 14 22 3.2.4 Calculation of SED/LED ...................................................................... 16 23 3.3 TOXICOLOGICAL EVALUATION .............................................................. 29 24 3.3.1. Irritation and corrosivity .................................................................... 31 25 3.3.2 Skin sensitisation .............................................................................. 35 26 3.3.3 Acute toxicity .................................................................................... 35 27 3.3.4 Repeated dose toxicity ....................................................................... 38 28 3.3.5 Reproductive toxicity ......................................................................... 42 29 3.3.6 Endocrine disrupting effects ................................................................ 51 30 3.3.6 Mutagenicity / genotoxicity ................................................................. 52 31 3.3.7 Carcinogenicity.................................................................................. 56 32 3.3.8 Photo-induced toxicity ........................................................................ 56 33 3.3.9 Human data ...................................................................................... 56 34 3.3.10 Special investigations ....................................................................... 56 35 3.4 SAFETY EVALUATION (including calculation of the MoS) ........................... 57 36 3.5 DISCUSSION .....................................................................................
Recommended publications
  • Methyl Salicylate and Menthol | Memorial Sloan Kettering Cancer Center

    Methyl Salicylate and Menthol | Memorial Sloan Kettering Cancer Center

    PATIENT & CAREGIVER EDUCATION Methyl Salicylate and Menthol This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US AMPlify Relief MM [OTC]; BenGay [OTC]; Calypxo HP [OTC]; Capasil [OTC]; Icy Hot [OTC]; Kwan Loong Pain Relieving [OTC]; Precise [OTC]; Salonpas Arthritis Pain [OTC]; Salonpas Jet Spray [OTC]; Salonpas Massage Foam [OTC]; Salonpas Pain Relief Patch [OTC]; Thera-Gesic Plus [OTC]; Thera-Gesic [OTC] What is this drug used for? It is used to ease muscle and joint aches and pain. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If your skin is damaged or has open wounds. Do not put on damaged skin or open wounds. If you are taking any other NSAID. If you are taking a salicylate drug like aspirin. If you are pregnant, plan to become pregnant, or get pregnant while taking this drug. This drug may cause harm to an unborn baby if taken at 20 weeks or later Methyl Salicylate and Menthol 1/7 in pregnancy. If you are between 20 to 30 weeks of pregnancy, only take this drug if your doctor has told you to. Do not take this drug if you are more than 30 weeks pregnant.
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm

    Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm

    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
  • Flavored Tobacco Products, Effective As of January 1, 2021

    Flavored Tobacco Products, Effective As of January 1, 2021

    ORDINANCE NO. ______ (CODE AMENDMENT NO. 772) AN ORDINANCE OF THE CITY COUNCIL OF THE CITY OF EL MONTE AMENDING CHAPTER 8.10 (RETAIL SALES OF TOBACCO PRODUCTS) OF TITLE 8 (HEALTH AND SAFETY) OF THE EL MONTE MUNICIPAL CODE TO PROHIBIT THE SALE OF FLAVORED TOBACCO PRODUCTS, EFFECTIVE AS OF JANUARY 1, 2021 WHEREAS, the potential failure of tobacco retailers to comply with tobacco control laws, particularly laws prohibiting the sale of tobacco products to minors, presents a threat to the public health, safety, and welfare of the residents of the City of El Monte (the “City”); WHEREAS, the federal Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act), enacted in 2009, prohibited candy- and fruit-flavored cigarettes,i largely because these flavored products were marketed to youth and young adults,ii and younger smokers were more likely than older smokers to have tried these products;iii WHEREAS, although the manufacture and distribution of flavored cigarettes (excluding menthol) are banned by federal law,iv neither federal law nor California law restricts the sale of menthol cigarettes or flavored non-cigarette tobacco products, such as cigars, cigarillos, smokeless tobacco, hookah tobacco, electronic smoking devices, and the solutions used in these devices; WHEREAS, flavored tobacco products are very common in California tobacco retailers as evidenced by the following: • 97.4% of stores that sell cigarettes sell menthol cigarettes;v • 94.5% of stores that sell little cigars sell them in flavored varieties;vi • 84.2% of stores
  • Poison Prevention Packaging: a Guide for Healthcare Professionals

    Poison Prevention Packaging: a Guide for Healthcare Professionals

    PPooiissoonn PPrreevveennttiioonn PPaacckkaaggiinngg:: AA GGuuiiddee FFoorr HHeeaalltthhccaarree PPrrooffeessssiioonnaallss REVISED 2005 CPSC 384 US. CONSUMER PRODUCT SAFETY COMMISSION, WASHINGTON, D.C. 20207 THIS BROCHURE BROUGHT TO YOU BY: U.S. CONSUMER PRODUCT SAFETY COMMISSION Washington, DC 20207 Web site: www.cpsc.gov Toll-free hotline: 1-800-638-2772 The U.S. Consumer Product Safety Commission (CPSC) is a federal agency that helps keep families and children safe in and around their homes. For more information, call the CPSC’s toll-free hotline at 1-800-638-2772 or visit its website at http://www.cpsc.gov. Poison Prevention Packaging: A Guide For Healthcare Professionals (revised 2005) Preface The U.S. Consumer Product Safety Commission (CPSC) administers the Poison Prevention Packaging Act of 1970 (PPPA), 15 U.S.C. §§ 1471-1476. The PPPA requires special (child-resistant and adult-friendly) packaging of a wide range of hazardous household products including most oral prescription drugs. Healthcare professionals are more directly involved with the regulations dealing with drug products than household chemical products. Over the years that the regulations have been in effect, there have been remarkable declines in reported deaths from ingestions by children of toxic household substances including medications. Despite this reduction in deaths, many children are poisoned or have "near-misses" with medicines and household chemicals each year. Annually, there are about 30 deaths of children under 5 years of age who are unintentionally poisoned. Data from the National Electronic Injury Surveillance System (a CPSC database of emergency room visits) indicate that in 2003, an estimated 78,000 children under 5 years of age were treated for poisonings in hospital emergency rooms in the United States.
  • Safety Assessment of Benzyl Salicylate As Used in Cosmetics

    Safety Assessment of Benzyl Salicylate As Used in Cosmetics

    Safety Assessment of Benzyl Salicylate As Used in Cosmetics Status: Draft Report for Panel Review Release Date: November 9, 2018 Panel Meeting Date: December 3-4, 2018 The 2018 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Alice Akinsulie, Scientific Writer/Analyst. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] Commitment & Credibility since 1976 Memorandum To: CIR Expert Panel Members and Liaisons From: Alice Akinsulie, Scientific Analyst/Writer Date: November 9, 2018 Subject: Draft Safety Assessment of Benzyl Salicylate as Used in Cosmetics Enclosed is the Draft Report of the Safety Assessment of Benzyl Salicylate as Used in Cosmetics. (It is identified as bensal122018rep in the pdf document.) On October 9, 2018, CIR issued the Scientific Literature Review (SLR) for this ingredient. According to the Dictionary, Benzyl Salicylate is reported to function mainly as a fragrance ingredient and light stabilizer. The Personal Care Products Council (Council) provided concentration of use survey data for the light stabilizer function (only) of Benzyl Salicylate. The results indicate that the light stabilizer concentrations of use for Benzyl Salicylate falls in the IFRA Standards for use of Benzyl Salicylate as a fragrance ingredient (identified as bensal122018data).
  • Preparation of Aspirin, Methyl Salicylate and Nylon Experiment #6

    Preparation of Aspirin, Methyl Salicylate and Nylon Experiment #6

    Preparation of Aspirin, Methyl Salicylate and Nylon Experiment #6 Objective: To observe the contrasts in appearance and odor of two different esters of salicylic acid, namely aspirin and methyl salicylate. The preparation of nylon will be demonstrated. Introduction Salicylic acid is a phenolic acid, indicating it has two functional groups on the benzene ring, an -OH group and a -COOH group. Aspirin and oil of wintergreen are esters of salicylic acid. Aspirin is the ester of salicylic acid and acetic acid (acetyl salicylic acid), whereas oil of wintergreen is the ester of salicylic acid and methanol (methyl salicylate). The chemical name for aspirin, acetyl salicylic acid, is not easily recognized as the name of an ester. However, the chemical name for oil of wintergreen, methyl salicylate, should readily be recognized as the name of an ester. In the preparation of aspirin the -OH group of salicylic acid reacts with the acetyl group of acetic acid or acetic anhydride to form acetyl salicylic acid. The formation of aspirin will proceed faster if acetic anhydride is used in place of acetic acid. However, acetic anhydride will hydrolyze in the presence of water to form acetic acid, slowing down the reaction. Hence, the reaction vessel must be very DRY to ensure a complete reaction. Sulfuric acid, H2SO4, is used as a dehydrating agent. The aspirin will be isolated by filtration and washed several times with ice cold deionized water to remove the water soluble impurities (acetic acid and sulfuric acid). Aspirin is quite insoluble in ice cold water, but is relatively soluble in warm water (1 g dissolves in 100 mL water at 37EC).
  • The Two Faces of Capsaicin

    The Two Faces of Capsaicin

    Published OnlineFirst April 12, 2011; DOI: 10.1158/0008-5472.CAN-10-3756 Cancer Review Research The Two Faces of Capsaicin Ann M. Bode and Zigang Dong Abstract Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is the principal pungent component in hot peppers, including red chili peppers, jalapeños, and habaneros. Consumed worldwide, capsaicin has a long and convoluted history of controversy about whether its consumption or topical application is entirely safe. Conflicting epidemiologic data and basic research study results suggest that capsaicin can act as a carcinogen or as a cancer preventive agent. Capsaicin is unique among naturally occurring irritant compounds because the initial neuronal excitation evoked is followed by a long-lasting refractory period, during which the previously excited neurons are no longer responsive to a broad range of stimuli. This process is referred to as desensitization and has been exploited for its therapeutic potential. Capsaicin-containing creams have been in clinical use for many years to relieve a variety of painful conditions. However, their effectiveness in pain relief is also highly debated and some adverse side effects have been reported. We have found that chronic, long-term topical application of capsaicin increased skin carcinogenesis in mice treated with a tumor promoter. These results might imply that caution should be exercised when using capsaicin-containing topical applications in the presence of a tumor promoter, such as, for example, sunlight. Cancer Res; 71(8); 2809–14. Ó2011 AACR. Introduction tion of gastric juice. The structure of capsaicin was partially solved by Nelson in 1919 (5), and the compound was originally Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide; Fig.
  • Excluded Drug List

    Excluded Drug List

    Excluded Drug List The following drugs are excluded from coverage as they are not approved by the FDA ACTIVE-PREP KIT I (FLURBIPROFEN-CYCLOBENZAPRINE CREAM COMPOUND KIT) ­ ACTIVE-PREP KIT II (KETOPROFEN-BACLOFEN-GABAPENTIN CREAM COMPOUND KIT) ­ ACTIVE-PREP KIT III (KETOPROFEN-LIDOCAINE-GABAPENTIN CREAM COMPOUND KIT) ­ ACTIVE-PREP KIT IV (TRAMADOL-GABAPENTIN-MENTHOL-CAMPHOR CREAM COMPOUND KIT) ­ ACTIVE-PREP KIT V (ITRACONAZOLE-PHENYTOIN SODIUM CREAM CMPD KIT) ­ ADAZIN CREAM (BENZO-CAPSAICIN-LIDO-METHYL SALICYLATE CRE) ­ AFLEXERYL-LC PAD (LIDOCAINE-MENTHOL PATCH) ­ AFLEXERYL-MC PAD (CAPSAICIN-MENTHOL TOPICAL PATCH) ­ AIF #2 DRUG PREPERATION KIT (FLURBIPROFEN-GABAPENT-CYCLOBEN-LIDO-DEXAMETH CREAM COMPOUND KIT) ­ AGONEAZE (LIDOCAINE-PRILOCAINE KIT) ­ ALCORTIN A (IODOQUINOL-HYDROCORTISONE-ALOE POLYSACCHARIDE GEL) ­ ALEGENIX MIS (CAPSAICIN-MENTHOL DISK) ­ ALIVIO PAD (CAPSAICIN-MENTHOL PATCH) ­ ALODOX CONVENIENCE KIT (DOXYCYCLINE HYCLATE TAB 20 MG W/ EYELID CLEANSERS KIT) ­ ANACAINE OINT (BENZOCAINE OINT) ­ ANODYNZ MIS (CAPSAICIN-MENTHOL DISK) ­ APPFORMIN/D (METFORMIN & DIETARY MANAGEMENT CAP PACK) ­ AQUORAL (ARTIFICIAL SALIVA - AERO SOLN) ­ ATENDIA PAD (LIDOCAINE-MENTHOL PATCH) ­ ATOPICLAIR CRE (DERMATOLOGICAL PRODUCTS MISC – CREAM) ­ Page 1 of 9 Updated JANUARY 2017 Excluded Drug List AURSTAT GEL/CRE (DERMATOLOGICAL PRODUCTS MISC) ­ AVALIN-RX PAD (LIDOCAINE-MENTHOL PATCH) ­ AVENOVA SPRAY (EYELID CLEANSER-LIQUID) ­ BENSAL HP (SALICYLIC ACID & BENZOIC ACID OINT) ­ CAMPHOMEX SPRAY (CAMPHOR-HISTAMINE-MENTHOL LIQD SPRAY) ­ CAPSIDERM PAD (CAPSAICIN-MENTHOL
  • Focuson MOUTHRINSES

    Focuson MOUTHRINSES

    v16F_mouthrinsetable_Layout 1 3/28/14 11:04 AM Page 30 FOCUSonMOUTHRINSES This informative table provides details about the therapeutic and cosmetic mouthrinses currently available. Do patients truly understand how mouthrinses work? Some may think of them as “magic bullets” that will cure their dental ailments with just a swish and spit. Oral health professionals, however, know that this is not the case. Patients still need advice on the proper usage and selection of mouthrinses, and the best resource for mouthrinse information is you—their dental hygienist. As the dental team member whose focus is prevention, your knowledge of mouthrinses is paramount to providing excellent patient care. With so many different mouthrinses on the market today, keeping up to date on the prod- ucts available is challenging. This Dimensions of Dental Hygiene mouthrinse guide is intended to help you sort through both the therapeutic and cosmetic mouthrinse options. When consider- ing over-the-counter therapeutic mouthrinses, noting which products have received the American Dental Association’s Seal of Acceptance is also helpful, as they have been evaluated for safety and efficacy. We hope you find this guide useful when making product recommen- dations to patients who wish to add rinsing to their daily oral care regimens. —Jill Rethman, RDH, BA Editor in Chief Note: Mouthrinse manufacturers in the United States were invited to submit information for this table. This list includes those companies that responded to our request for information. There may be inadvertent
  • Topical Analgesics: Expensive and Avoidable

    Topical Analgesics: Expensive and Avoidable

    TOPICAL ANALGESICS: EXPENSIVE AND AVOIDABLE FAST FOCUS Some very expensive topical creams and gels are creeping into the workers’ compensation Close management of custom compounds prescription files. Previously, the issue of custom compounds was highlighted and the has decreased their prevalence in workers’ attention to these prescriptions has resulted in a decrease in the number of prescriptions compensation. But private-label topicals and homeopathic products have filled the void. seen. However, the price of these compounds has increased significantly. Neither is FDA-approved. Both warrant close monitoring because of their high costs and In addition to the compounds that are still being prescribed, other topical products are lack of proven efficacy. increasingly seen in the workers’ compensation setting. In this article, a spotlight is turned on to expose more expensive topicals — private-label analgesics and homeopathic products. 24 | RxInformer FALL 2013 SUMMARY OF PRIMARY ISSUES Issue Custom Compounds Private-Label Analgesics Homeopathic Products NDCs Available FDA-approved Proven clinical benefit Prepared by compounding — — pharmacy for a specific patient Contain high levels of NSAIDs — — Contain 2-3x the FDA-approved concentration of methyl salicylate — and/or menthol Can cause skin burns — Prescribers unaware of compound ingredients Prescribers unaware of high costs Expiration dating required — — TOPICAL PRIVATE-LABEL PRODUCTS FINANCIAL CONCERNS There are private-label companies marketing products similar to inexpensive, over- When compared with comparable over-the- the-counter products, but with catchy names, inflated claims and prices. Private-label counter (OTC) preparations, the private-label topical compounds are products containing OTC ingredients such as high-potency products’ prices are stunning.
  • Experiment 22 Synthesis of Aspirin and Oil of Wintergreen

    Experiment 22 Synthesis of Aspirin and Oil of Wintergreen

    Experiment 22 Synthesis of Aspirin and Oil of Wintergreen GOALS: In this two-week experiment the important area of organic chemistry will be illustrated by the preparation and characterization of two compounds. The usefulness of functional groups will be illustrated as well as the use of NMR, IR, and melting point in characterizing a product. The analysis will be done next week in Experiment 23. INTRODUCTION: Synthesis and use of organic compounds is an extremely important area of modern chemistry. Approximately half of all chemists work with organic chemicals. In everyday life, many if not most of the chemicals you come in contact with are organic chemicals. Examples include drugs, synthetic fabrics, paints, plastics, etc. Synthesis of Aspirin and Methyl Salicylate. The two compounds we will be preparing, aspirin (acetylsalicylic acid) and oil of wintergreen (methyl salicylate), are both organic esters. An ester is a compound that is formed when an acid (containing the –COOH group) reacts with an alcohol (a compound containing an –OH group). O O + C O C + O Eqn 1 R O H 1 H R2 R O R H H 1 2 ester water acid alcohol Here R1 and R2 represent groups such as CH3– or CH3CH2–. The reaction type shown above may be called a condensation reaction because the small molecule H2O is eliminated from the reactants while the remaining bits of the reactants condense together to give the main product. This reaction may also be called an esterification, since the product of the reaction is an ester, a compound containing the CO2R group (see chapter 20 for definitions of acids, esters, and alcohols).
  • Safety Assessment of Benzyl Salicylate As Used in Cosmetics

    Safety Assessment of Benzyl Salicylate As Used in Cosmetics

    Safety Assessment of Benzyl Salicylate As Used in Cosmetics Status: Scientific Literature Review for Public Comment Release Date: October 9, 2018 Panel Meeting Date: December 3-4, 2018 All interested persons are provided 60 days from the above release date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth. The 2018 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Alice Akinsulie, Scientific Writer/Analyst. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] INTRODUCTION This scientific literature review is the initial step in preparing a safety assessment of Benzyl Salicylate as used in cosmetic formulations.